[Urinary tract infections. Therapeutic failures and course monitoring (author's transl)].
The proportion of reinfections and relapses in urinary tract infections amounts to about 35-70%. Hydrokinetic conditions (e.g. size of bladder, frequency of micturition, rate of multiplication of the pathogens, adhesiveness of bacteria) not seldom lead to a discrepancy between the in vivo response of the pathogen to the chemotherapeutic agent and the corresponding MIC determined in vitro. Ten causes for the therapeutic failure are discussed in greater detail. Monitoring the course in good time with due regard to the risks is essential. A scheme for microbiological monitoring investigations before beginning therapy, during treatment and after discontinuing the medicament, as well as for long term therapy is suggested.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002176:Candida albicans / Q000254:growth & development; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012008:Recurrence; D012703:Serotyping; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D005839:Gentamicins
Harnwegsinfektionen. Therapieversagen und Verlaufskontrolle.